Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 1.00 |
| ▸ | PPP6C | O00743 | 1/20 | 1.00 |
| ▸ | PPP1CC | P36873 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | PPP5C | P53041 | 1/20 | 1.00 |
| ▸ | PPP2CA | P67775 | 1/20 | 1.00 |
| ▸ | PPP2R5A | Q15172 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calyculin A SCHEMBL4295478 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin A SCHEMBL82924 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin B SCHEMBL29809573 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin A SCHEMBL4299349 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin A SCHEMBL82925 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin A SCHEMBL29406338 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| SCHEMBL15919331 | 0.95 | PTPN1 (0.91) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin SCHEMBL1443597 | 0.94 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin SCHEMBL29536011 | 0.94 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin SCHEMBL4291014 | 0.94 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117305224-A | Method for obtaining definitive endoderm cells from human pluripotent stem cells by differentiation using myosin activator or Piezo1 activator | 武汉大学 | 2023-12-29 | — | — | CN | disclosed |
| US-20210095288-A1 | METHODS OF MODULATING NKX6.3 | NESTLE SA (CH) | 2021-04-01 | — | — | US | disclosed |
| EP-3773571-A1 | PREVENTION OR TREATMENT OF CHRONIC ORGAN INJURY | Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin (DE) | 2021-02-17 | — | — | EP | disclosed |
| US-20210008044-A1 | PREVENTION OR TREATMENT OF CHRONIC ORGAN INJURY | GEORG-AUGUST-UNIVERSITAET GOETTINGEN, STIFTUNG OEFFENTLICHEN RECHTS, UNIVERSITAETSMEDIZIN (DE) | 2021-01-14 | — | — | US | disclosed |
| CN-112088216-A | Methods of modulating NKX6.3 | 雀巢产品有限公司 | 2020-12-15 | — | — | CN | disclosed |
| WO-2019185708-A1 | PREVENTION OR TREATMENT OF CHRONIC ORGAN INJURY | GEORG-AUGUST-UNIVERSITAET GOETTINGEN, STIFTUNG OEFFENTLICHEN RECHTS, UNIVERSITAETSMEDIZIN (DE) | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008044-A1 | PREVENTION OR TREATMENT OF CHRONIC ORGAN INJURY | FKBP2, DUSP3, FKBP1A | PTPN1 202/4885PPP6C 31/4885PPP1CC 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.